Browse the complete Report Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy growth surpassed by generic erosion
Browse All Datamonitor Research Reports
Datamonitor estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a decline to $4.2 billion by 2019. The greatest threat to the market is generics, with drug classes having differing vulnerability to generic erosion. While the symptomatic treatment sales will decrease, immunotherapy sales are on the rise, with changing regulations dictating development.
Scope
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
- Assessment of key drug classes for allergic rhinitis, with analysis of impacting events and a 10 year sales forecast split by indication
- In-depth discussion of the role of immunotherapy in allergic rhinitis, with analysis of developments, regulations, and pipeline products
- Interactive patient-based forecasts of 3 immunotherapy products, with a discussion of their relative strengths and weaknesses
Datamonitor estimates 2009 allergic rhinitis sales in the seven major markets of $5 billion. This is forecast to drop to $4.2 billion in 2019, driven by the entrance of cheap generics, most notably in the US. Oral antihistamines are the more vulnerable to generic erosion, while nasal corticosteroids are partially protected by their device.
Reformulation of molecules and combinations are common, but timing is key. In 2009, Merck’s Clarinex (desloratadine) had a quarter of Claritin’s (loratadine) peak sales, having launched after generics. Meda Pharma’s azelastine follow-on has seen more success launching prior to patent expiry and Meda Pharma is now combining the drug with a steroid.
Changing regulations are driving development of immunotherapies, with large-scale development programs seen in recent years. While immunotherapy is expected to remain a niche market, significant growth is forecast. Two sublingual grass tablets, Grazax (ALK-Abelló) and Oralair (Stallergènes) forecast to have sales of $250m in the US and EU by 2019.
Reasons to Purchase
- Understand allergic rhinitis market trends, including life cycle management, current sales, and a 10 year sales forecast of symptomatic treatments
- Gain insight into the immunotherapy market and access patient based forecasts of three key immunotherapy products, with interactive assumptions
- Use analysis of key companies in the market and see how allergic rhinitis contributes to total brand sales
OVERVIEW 1Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Immunology & Inflammation pharmaceutical analysis team 2
EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the allergic rhinitis market 3
Related reports 4
Upcoming related reports 4
Table of Contents 4
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas,
TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/
Original Source: Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy growth surpassed by generic erosion
Buy Now: Datamonitor Research Reports
